selected scholarly activity
-
chapters
- Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. Advances in Clinical Chemistry. 11-79. 2005
-
conferences
- Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biological Chemistry. 749-759. 2006
- Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. Journal of Investigative Dermatology. A57-A57. 2005
- Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.. Clinical Cancer Research. 3260-3270. 2000
- Determination of pepsinogen C concentration in breast tumor cytosols by a highly sensitive immunofluorometric assay and its association with ether prognostic variables.. Clinical Chemistry. A117-A117. 1999
- ELISA-determined p21(WAF1) expression does not correlate with non-small cell lung cancer aggressiveness.. Clinical Chemistry. A111-A111. 1999
- Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort.. Journal of Clinical Oncology. 2641-2650. 1998
- Prognostic significance of quantitatively-analyzed p53 protein accumulation in lung carcinoma.. Clinical Chemistry. A42-A42. 1998
- p53 and WAF1 expression in epithelial ovarian cancer: Prognostic and predictive implications. European Journal of Cancer. S22-S22. 1998
- ELISA-detected p53 protein accumulation is a prognostic factor in a large cohort of breast cancer patients.. Clinical Chemistry. 566-566. 1997
- Frequency of prostate specific antigen mRNA expression in lung tumors.. Clinical Chemistry. 582-582. 1997
- Associations between PSA and IGF-I, IGF-II, IGFBP-1, and IGFBP-3 in breast cancer.. Clinical Chemistry. 703-703. 1996
- Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer.. Clinical Chemistry. 694-694. 1996
- P53 protein is absent from the serum of patients with lung cancer.. Clinical Chemistry. 695-695. 1996
- EXPRESSION OF CD44 ON HUMAN RETINAL-PIGMENT EPITHELIAL-CELLS. Molecular Biology of the Cell. 960-960. 1995
- EXPRESSION OF THE PROSTATE-SPECIFIC ANTIGEN GENE IN A PRIMARY OVARIAN-CARCINOMA. Clinical Chemistry. S219-S219. 1995
- IMMUNOFLUOROMETRICALLY QUANTIFIED P53 PROTEIN AS A PROGNOSTIC INDICATOR IN OVARIAN-CARCINOMA. Clinical Chemistry. S224-S224. 1995
- QUANTITATIVE-ANALYSIS OF MUTANT P53 PROTEIN IN BREAST-CARCINOMA - RELATIONSHIPS TO OTHER PROGNOSTIC FACTORS. Clinical Chemistry. S224-S224. 1995
- PREDICTIVE VALUE OF RENAL BIOPSY IN PATIENTS WITH FOCAL AND DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS TREATED WITH INTRAVENOUS CYCLOPHOSPHAMIDE. Laboratory Investigation. A158-A158. 1995
-
journal articles
- Quantification of Eight Tissue Kallikreins in the Stratum Corneum and Sweat. Journal of Investigative Dermatology. 126:927-931. 2006
- Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma. Tumor Biology. 27:1-7. 2006
- Quantification of Human Tissue Kallikreins in the Stratum Corneum: Dependence on Age and Gender. Journal of Investigative Dermatology. 125:1182-1189. 2005
- Human Kallikrein 4: Quantitative Study in Tissues and Evidence for Its Secretion into Biological Fluids. Clinical Chemistry. 51:1432-1442. 2005
- Cloning, physical mapping and structural characterization of the human α A -adaptin gene. Gene. 289:191-199. 2002
- Do wine polyphenols modulate p53 gene expression in human cancer cell lines?. Clinical Biochemistry. 34:415-420. 2001
- IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal of Cancer. 37:478-485. 2001
- Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. Breast Cancer Research and Treatment. 61:111-119. 2000
- p21WAF1 protein expression determined by quantitative immunoassay in relation to non-small-cell lung cancer aggressiveness. Journal of Cancer Research and Clinical Oncology. 126:48-52. 2000
- Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. British Journal of Cancer. 82:361-367. 2000
- Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal of Cancer. 81:490-495. 1999
- Moderate alcohol consumption: the gentle face of Janus. Clinical Biochemistry. 32:505-518. 1999
- Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.. Clinical Cancer Research. 5:1778-1785. 1999
- Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.. Anticancer Research. 19:749-756. 1999
- METHOD-DEPENDENT BIAS IN THE QUANTITATION OFCIS- ANDTRANS-RESVERATROL GLUCOSIDES BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY. Journal of Liquid Chromatography and Related Technologies. 22:1843-1855. 1999
- Insulin-like growth factor–binding protein-3 and breast cancer survival. International Journal of Cancer. 79:624-628. 1998
- Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. International Journal of Cancer. 79:494-501. 1998
- Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.. Clinical Cancer Research. 4:1489-1497. 1998
- Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. International Journal of Cancer. 79:147-152. 1998
- Exon 5 of the p53 gene is a target for deletions in ovarian cancer. Clinical Chemistry. 44:72-77. 1998
- Frequency of Expression of Prostate-Specific Antigen mRNA in Lung Tumors. American Journal of Clinical Pathology. 108:184-190. 1997
- Comparison of Immunofluorometry and Immunohistochemistry for the Detection of p53 Protein in Lung Cancer Specimens. American Journal of Clinical Pathology. 107:308-316. 1997
- p53 protein is absent from the serum of patients with lung cancer. British Journal of Cancer. 74:1434-1440. 1996
- Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal of Cancer. 74:1242-1247. 1996
- Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Research and Treatment. 40:171-178. 1996
- Time-resolved immunofluorometric assay of p53 protein. Clinical Chemistry. 41:1720-1729. 1995
- Time-resolved immunofluorometric assay of p53 protein.. Clinical Chemistry. 41:1720-1729. 1995
- Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. British Journal of Cancer. 72:720-727. 1995
- Prostate-specific antigen in serum of women with breast cancer. British Journal of Cancer. 72:728-731. 1995
- Prognostic value of immunofluorometrically quantifed P53 protein in ovarian carcinoma. Clinical Biochemistry. 28:341-341. 1995
- Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.. Cancer Research. 55:2104-2110. 1995
- Expression of the prostate-specific antigen gene by a primary ovarian carcinoma.. Cancer Research. 55:1603-1606. 1995
- Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 75:1327-1338. 1995
- Assessment of p53 overexpression by non‐immunohistochemical methods. Journal of Pathology. 175:93-94. 1995
- Immunoreactive prostate‐specific antigen in lung tumors. Journal of Clinical Laboratory Analysis. 9:375-379. 1995
- Prostate‐Specific antigen expression by various tumors. Journal of Clinical Laboratory Analysis. 9:123-128. 1995
- Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. Journal of Clinical Laboratory Analysis. 8:251-253. 1994
- Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Research and Treatment. 30:179-195. 1994